BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 31340943)

  • 1. Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide.
    Tan J; Sano H; Poole K
    BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31340943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriparatide treatment in an adult patient with hypophosphatasia exposed to bisphosphonate and revealed by bilateral atypical fractures.
    Righetti M; Wach J; Desmarchelier R; Coury F
    Joint Bone Spine; 2018 May; 85(3):365-367. PubMed ID: 29246529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report.
    Ramchand SK; Chiang CY; Zebaze RM; Seeman E
    Osteoporos Int; 2016 Feb; 27(2):821-5. PubMed ID: 26458389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration.
    Miller PD; McCarthy EF
    Semin Arthritis Rheum; 2015 Apr; 44(5):477-482. PubMed ID: 25312241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium.
    Lee JK
    Int J Rheum Dis; 2009 Jul; 12(2):149-54. PubMed ID: 20374333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of atypical femoral fracture in a patient with osteogenesis imperfecta.
    Tan JY; Seow CJ
    BMJ Case Rep; 2017 Dec; 2017():. PubMed ID: 29269360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management after first-line antiresorptive treatment for postmenopausal osteoporosis.
    Paccou J
    Joint Bone Spine; 2016 Jul; 83(4):373-5. PubMed ID: 26992951
    [No Abstract]   [Full Text] [Related]  

  • 8. Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur.
    Greenspan SL; Vujevich K; Britton C; Herradura A; Gruen G; Tarkin I; Siska P; Hamlin B; Perera S
    Osteoporos Int; 2018 Feb; 29(2):501-506. PubMed ID: 29085957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rare case of a bisphosphonate-induced peri-prosthetic femoral fracture.
    Cross MB; Nam D; van der Meulen MC; Bostrom MP
    J Bone Joint Surg Br; 2012 Jul; 94(7):994-7. PubMed ID: 22733959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report.
    Huang HT; Kang L; Huang PJ; Fu YC; Lin SY; Hsieh CH; Chen JC; Cheng YM; Chen CH
    Menopause; 2012 Dec; 19(12):1360-3. PubMed ID: 22968250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
    Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures.
    Starr J; Tay YKD; Shane E
    Curr Osteoporos Rep; 2018 Aug; 16(4):519-529. PubMed ID: 29951870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A probable atypical ulnar fracture in a man receiving denosumab.
    Binkley N; Goel H; Shives E; Krueger D; Hare K
    Bone; 2021 Feb; 143():115726. PubMed ID: 33130001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conservative treatment of recurrent symptoms of an incomplete, atypical femoral fracture associated with glucocorticoid, bisphosphonate, and denosumab therapy in a patient with chronic obstructive pulmonary disease.
    Lai KH; Chiang CY; Yang RS; Yang KC; Wu CC
    Acta Clin Belg; 2019 Oct; 74(5):370-374. PubMed ID: 30336748
    [No Abstract]   [Full Text] [Related]  

  • 16. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
    Leder BZ; Tsai JN; Jiang LA; Lee H
    Bone; 2017 May; 98():54-58. PubMed ID: 28286299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
    N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report.
    Thompson RN; Armstrong CL; Heyburn G
    Bone; 2014 Apr; 61():44-7. PubMed ID: 24389366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate long-term treatment related bilateral subtrochanteric femoral fracture. Can teriparatide be useful?
    Tarazona-Santabalbina FJ; Aguilella-Fernández L
    Aging Clin Exp Res; 2013 Oct; 25(5):605-9. PubMed ID: 24026625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review.
    Selga J; Nuñez JH; Minguell J; Lalanza M; Garrido M
    Osteoporos Int; 2016 Feb; 27(2):827-32. PubMed ID: 26501556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.